Abstracts tagged "Patient reported outcomes"

Abstract Number: 0361 • ACR Convergence 2021
Factors Associated with Engaging in Physical Activity in Axial Spondyloarthritis. Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, David Gálvez-Ruiz⁷, Pedro Plazuelo-Ramos⁸ and Denis Poddubnyy⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Physical activity is an essential component in axial spondyloarthritis (axSpA) care, improving physical and mental wellbeing. This analysis aims to identify factors associated with…
Abstract Number: 0718 • ACR Convergence 2021
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
Harmony Tsui¹, Mianbo Wang², Mathieu Piché³, Alexandra Ladouceur⁴, Evelyne Vinet⁵, Alexandra Albert⁶, Maggie Larche⁷, Annaliese Tisseverasinghe⁸, Marie Hudson¹ and Valerie Leclair⁹, ¹McGill University, Montréal, QC, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada, ⁴McGill University Health Center, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada, ⁶CHU de Quebec, Québec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹McGill University, Karolinska Insitutet, Montréal, QC, Canada
Background/Purpose: Although pain is one of the most common and highest priority symptoms reported by people with autoimmune inflammatory myopathies (AIM), large descriptive studies on…
Abstract Number: 0757 • ACR Convergence 2021
Different Versions of the Patient Global Question in Rheumatoid Arthritis – Does It Really Matter? – Results of a Multi-center Observational Study
Paul Studenic¹, Aliaksandra Baranskaya², Stanley Cohen³, Nancy Shadick⁴, Christine Iannaccone⁵, Maria Dahl Mjaavatten⁶, Elisabeth Lie⁷, Tore Kvien⁸, Josef Smolen⁹, Daniel Aletaha¹⁰ and Helga Radner⁹, ¹Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ²Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Brigham & Women's Hospital, Boston, MA, ⁵Brigham and Women’s Hospital, Topsfield, MA, ⁶Diakonhjemmet Hospital, Haslum, Norway, ⁷Diakonhjemmet Hospital, Oslo, Nepal, ⁸Diakonhjemmet Hospital, Oslo, Norway, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Medical University Vienna, Vienna, Austria
Background/Purpose: The patient global assessment (PGA), typically assessed as 'Considering all of the ways your arthritis has affected you, how do you feel your arthritis…
Abstract Number: 0845 • ACR Convergence 2021
A Non-Interventional Prospective Observational Study of Treatment with Etanercept Biosimilar (SB4) in Rheumatoid Arthritis in Real Life Clinical Practice; Interim Analysis of the ‘BENEFICIAL’ Study
Panagiotis Athanassiou¹, Andreas Bounas², Dimitrios Boumpas³, Prodromos Sidiropoulos⁴, Christina Tsalapaki⁵, Alexandros Garyfallos⁶, Eleftheria Grika⁷, Paraskevi Voulgari⁸, Angeliki Kekki⁹, Zafeirios Anagnostopoulos⁹, Georgios Karachalios⁹ and Nikos Antonakopoulos⁹, ¹Department of Rheumatology, St. Paul’s Hospital of Thessaloniki, Thessaloniki, Greece, ²General Clinic of Patras “Olympion”, Rheumatology, Patras, Greece, ³“Attikon” University Hospital, Rheumatology and Clinical Immunology Unit ,4th University Pathology Clinic, Athens, Greece, ⁴Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ⁵General Hospital of Athens “Hippokratio", Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁶General Hospital of Thessaloniki “Ippokratio" , Τhessaloniki, Greece, Thessaloniki, Greece, ⁷Rheumatology Clinic, General Hospital “Evangelismos”, Athens, Greece, ⁸Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ⁹Genesis Pharma SA, Athens, Greece, Athens, Greece
Background/Purpose: SB4 is an etanercept biosimilar that obtained EU regulatory approval in 2016, and became available in Greece in 2018. Due to lack of published…
Abstract Number: 1202 • ACR Convergence 2021
Widespread but Not Regional Non-articular Pain Influences Patient and Rheumatologist Reported Change in Clinical Disease Activity Index Scores over Time – Implications for Using Patient Ratings in Telehealth – a Study from the Canadian Early Arthritis Cohort
Vivian Bykerk¹, Orit Schieir², Marie-France Valois³, Glen Hazlewood⁴, Gilles Boire⁵, Carol Hitchon⁶, Louis Bessette⁷, Diane Tin⁸, Edward Keystone⁹, Carter Thorne⁸, Janet Pope¹⁰ and Susan Bartlett³, ¹Hospital for Special Surgery, New York, NY, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada
Background/Purpose: During the COVID pandemic assessments of RA disease activity (DA) have relied on virtual assessments by patient report. It is unknown whether non-articular pain…
Abstract Number: 1332 • ACR Convergence 2021
Validation of the PROMIS-29 Profile in Patients with Active Psoriatic Arthritis Using Data from a Phase 3, Randomized, Placebo-Controlled Study Evaluating Guselkumab (TREMFYA®)
Ana-Maria Orbai¹, Laura Coates², Atul Deodhar³, Christopher Ritchlin⁴, Alexa Kollmeier⁵, Marlies Neuhold⁶, Yi-Hsuan Liu⁷, Yan Liu⁷ and Chenglong Han⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen-Cilag, Zug, Switzerland, ⁷Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: It is important to assess symptoms of pain, fatigue, anxiety, depression, sleep disturbance, and impaired physical function in patients (pts) with psoriatic arthritis (PsA),…
Abstract Number: 1621 • ACR Convergence 2021
Self-reported Transition Readiness of Adolescent Patients with Rheumatologic Disease: Do the Parents Agree?
Christina Ma¹, Molly Dushnicky¹, Habeba Talaat¹, Steffy Thomas¹, Karen Beattie¹, Tania Cellucci², Stephanie Garner¹, Liane Heale¹, Mark Matsos¹ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased disease activity and morbidity. The parent-child relationship is a significant relationship in…
Abstract Number: PP09 • ACR Convergence 2021
Family Planning while Living with Rheumatoid Arthritis
Shannan O'Hara-Levi, Monroe, NY
Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
Abstract Number: 0366 • ACR Convergence 2021
Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Souzi Makri⁴, Laura Christen⁵, José Correa-Fernández⁶, Sergio Sanz-Gomez⁶, Raj Mahapatra⁷, Carlos Jesús Delgado-Domínguez⁶ and Denis Poddubnyy⁸, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁷Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁸Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: AxSpA is associated with substantial negative consequences regarding work status and career prospects. The aim is to identify factors associated with barriers to job…
Abstract Number: 0724 • ACR Convergence 2021
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
Martin Boucher¹, Kenneth Verburg², Puneet Gaitonde² and Scott marshall¹, ¹Pfizer R&D Ltd., Sandwich, United Kingdom, ²Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized monoclonal antibody against nerve growth factor that has been evaluated for relief of chronic osteoarthritis pain by subcutaneous (SC) or…
Abstract Number: 0759 • ACR Convergence 2021
The Patient as Assessor of Disease Status: A Graphical Evaluation of Relations Between Patient-Reported Outcomes in Early Rheumatoid Arthritis
Diederik De Cock¹, Gert Verhavert¹, Sofia Pazmino¹, Delphine Bertrand¹, Michal Doumen¹, Rene Westhovens² and Patrick Verschueren³, ¹KU Leuven, Leuven, Belgium, ²University Hospitals KU Leuven, Maaseik, Belgium, ³University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: Current EULAR-guidelines recommend treating Rheumatoid Arthritis (RA) early, intensively and to-target. Patient-Reported Outcomes (PROs) can be important contributors for remote monitoring of disease status…
Abstract Number: 0849 • ACR Convergence 2021
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Creating a Foundation for Linking Patient Reported Outcomes Measures with the International Classification of Functioning, Disability and Health
Hannah Bailey¹, Ananya Vasudevan¹, Emily Hickey², Aileen Ledingham³, Mary Slavin¹, Lewis Kazis⁴ and Ronald Tompkins⁵, ¹Boston University School of Public Health, Boston, MA, ²University of Wisconsin, Madison, WI, ³Boston University School of Public Health, Waltham, MA, ⁴Boston University, Spaulding Hospital and Harvard Medical School, Boston, MA, ⁵Harvard Medical School, Boston, MA
Background/Purpose: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a devastating multi-system chronic disease, estimated to affect 1.5 million adults in the United States. The disease is…
Abstract Number: 1203 • ACR Convergence 2021
A Change in a Patient Informed Clinical Disease Activity Index (PTCDAI) Is Similar to Their Rheumatologists CDAI When Following Patients with Early RA in the Canadian Early Arthritis Cohort (CATCH) Study
Vivian Bykerk¹, Orit Schieir², Marie-France Valois³, Glen Hazlewood⁴, Carol Hitchon⁵, Gilles Boire⁶, Diane Tin⁷, Louis Bessette⁸, Edward Keystone⁹, Carter Thorne⁷, Janet Pope¹⁰ and Susan Bartlett³, ¹Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Laval University, Québec City, QC, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada
Background/Purpose: The Clinical Disease Activity Index (CDAI) is a frequently used composite measure by rheumatologists (MD) in routine care used to guide target-based treatment decisions.…
Abstract Number: 1333 • ACR Convergence 2021
Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
Peter Nash¹, Lai-Shan Tam², Wen-Chan Tsai³, Ying-Ying Leung⁴, Daniel Furtner⁵, Shihong Sheng⁶, Yanli Wang⁶, May Shawi⁷, Alexa Kollmeier⁸, Jonathan Sherlock⁹ and Daniel Cua⁶, ¹Griffith University, Brisbane, Australia, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic), ³Janssen Research & Development, LLC, Kaohsiung City, Taiwan (Republic of China), ⁴Singapore General Hospital and Duke-NUS Medical School, Singapore, Singapore, ⁵Janssen, a division of Johnson & Johnson Pte. Ltd., Singapore, Singapore, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Oxford, Spring House, PA
Background/Purpose: Guselkumab (GUS), a targeted inhibitor of IL-23p19, demonstrated significant efficacy v placebo (PBO) in achieving ACR20 response at week (W) 24 in patients (pts)…
Abstract Number: 1624 • ACR Convergence 2021
Patient-Reported Care Utilization, Socioeconomic Status, and Health Status Among Young Adults with JIA
Emily Smitherman¹, Rouba Chahine¹, Nicole Bitencourt², AKM Rahman¹, Erica Lawson³ and Joyce Chang⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Loma Linda University Medical Center, Redlands, CA, ³University of California San Francisco, San Francisco, CA, ⁴Boston Children's Hospital, Brookline, MA
Background/Purpose: Young adulthood is a vulnerable period for individuals with childhood-onset rheumatic diseases, especially the transition from pediatric to adult care. Our objective was to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].